Invest 104 , 16031612 (1999)
Investments are significant in the region, driving rapid product launches, clinical trials for new indications, and early adoption of innovative GLP-1 formulations, including oral and long-acting injectables
2 RESEARCH METHODOLOGY 48 5 MARKET OVERVIEW Pharmaceutical giants fuel GLP-1 market expansion, driven by obesity prevalence and innovative oral treatments
Slowly increasing the dose of a GLP-1 medication allows the body time to adjust to the changes that are occurring, especially the slowing of gastric motility, says Currier, So the key to avoiding the nausea as much as possible is to take the titration phase slowly and allow the body time to acclimate appropriately. If someone increases the dose too quickly or overdoses, theyre more likely to experience severe nausea
adults now takes a GLP-1, but that average hides a sharp pattern by age